| Prevalence and clinical outcomes of COVID-19 in patients with autoimmune diseases: a systematic review and meta-analysis S Akiyama, S Hamdeh, D Micic, A Sakuraba Annals of the rheumatic diseases 80 (3), 384-391, 2021 | 415 | 2021 |
| Clostridium difficile Ribotype Does Not Predict Severe Infection ST Walk, D Micic, R Jain, ES Lo, I Trivedi, EW Liu, LM Almassalha, ... Clinical infectious diseases 55 (12), 1661-1668, 2012 | 237 | 2012 |
| Effect of COVID-19 pandemic lockdowns on planned cancer surgery for 15 tumour types in 61 countries: an international, prospective, cohort study J Glasbey, A Ademuyiwa, A Adisa, E AlAmeer, AP Arnaud, F Ayasra, ... The Lancet Oncology 22 (11), 1507-1517, 2021 | 234 | 2021 |
| Risk of gastrointestinal cancers in patients with cystic fibrosis: a systematic review and meta-analysis A Yamada, Y Komaki, F Komaki, D Micic, S Zullow, A Sakuraba The Lancet Oncology 19 (6), 758-767, 2018 | 192 | 2018 |
| Clostridium difficile Ribotype 027: Relationship to Age, Detectability of Toxins A or B in Stool With Rapid Testing, Severe Infection, and Mortality K Rao, D Micic, M Natarajan, S Winters, MJ Kiel, ST Walk, K Santhosh, ... Clinical Infectious Diseases 61 (2), 233-241, 2015 | 160 | 2015 |
| Predicting outcomes to optimize disease management in inflammatory bowel diseases J Torres, F Caprioli, KH Katsanos, T Lobatón, D Micic, M Zerôncio, ... Journal of Crohn's and Colitis 10 (12), 1385-1394, 2016 | 147 | 2016 |
| Systematic review with meta‐analysis: the efficacy and safety of CT‐P13, a biosimilar of anti‐tumour necrosis factor‐α agent (infliximab), in inflammatory bowel diseases Y Komaki, A Yamada, F Komaki, D Micic, A Ido, A Sakuraba Alimentary pharmacology & therapeutics 45 (8), 1043-1057, 2017 | 127 | 2017 |
| Outcome of pregnancy and neonatal complications with anti-tumor necrosis factor-α use in females with immune mediated diseases; a systematic review and meta-analysis F Komaki, Y Komaki, D Micic, A Ido, A Sakuraba Journal of autoimmunity 76, 38-52, 2017 | 97 | 2017 |
| Safety and efficacy of combination treatment with calcineurin inhibitors and vedolizumab in patients with refractory inflammatory bowel disease B Christensen, PR Gibson, D Micic, RJ Colman, SR Goeppinger, ... Clinical Gastroenterology and Hepatology 17 (3), 486-493, 2019 | 92 | 2019 |
| Vedolizumab in patients with concurrent primary sclerosing cholangitis and inflammatory bowel disease does not improve liver biochemistry but is safe and effective for the … B Christensen, D Micic, PR Gibson, A Yarur, E Bellaguarda, P Corsello, ... Alimentary pharmacology & therapeutics 47 (6), 753-762, 2018 | 81 | 2018 |
| Successful immunotherapy with IL-2/anti-CD40 induces the chemokine-mediated mitigation of an immunosuppressive tumor microenvironment JM Weiss, TC Back, AJ Scarzello, JJ Subleski, VL Hall, JK Stauffer, ... Proceedings of the National Academy of Sciences 106 (46), 19455-19460, 2009 | 76 | 2009 |
| Poor Functional Status as a Risk Factor for Severe Clostridium difficile Infection in Hospitalized Older Adults K Rao, D Micic, E Chenoweth, L Deng, AT Galecki, C Ring, VB Young, ... Journal of the American Geriatrics Society 61 (10), 1738-1742, 2013 | 74 | 2013 |
| The systemic inflammatory response to Clostridium difficile infection K Rao, JR Erb-Downward, ST Walk, D Micic, N Falkowski, K Santhosh, ... PLoS One 9 (3), e92578, 2014 | 71 | 2014 |
| Efficacy, safety and pharmacokinetics of biosimilars of anti-tumor necrosis factor-α agents in rheumatic diseases; A systematic review and meta-analysis Y Komaki, A Yamada, F Komaki, P Kudaravalli, D Micic, A Ido, ... Journal of autoimmunity 79, 4-16, 2017 | 65 | 2017 |
| Procalcitonin levels associate with severity of Clostridium difficile infection K Rao, ST Walk, D Micic, E Chenoweth, L Deng, AT Galecki, R Jain, ... PLoS One 8 (3), e58265, 2013 | 53 | 2013 |
| Serologic response to coronavirus disease 2019 (COVID-19) vaccination in patients with immune-mediated inflammatory diseases: a systematic review and meta-analysis A Sakuraba, A Luna, D Micic Gastroenterology 162 (1), 88-108. e9, 2022 | 52 | 2022 |
| Risk of cancer recurrence among individuals exposed to antitumor necrosis factor therapy: a systematic review and meta-analysis of observational studies D Micic, Y Komaki, A Alavanja, DT Rubin, A Sakuraba Journal of clinical gastroenterology 53 (1), e1-e11, 2019 | 52 | 2019 |
| Systematic review with meta‐analysis: risk of new onset IBD with the use of anti‐interleukin‐17 agents A Yamada, J Wang, Y Komaki, F Komaki, D Micic, A Sakuraba Alimentary Pharmacology & Therapeutics 50 (4), 373-385, 2019 | 51 | 2019 |
| Vedolizumab as induction and maintenance for inflammatory bowel disease: 12-month effectiveness and safety B Christensen, RJ Colman, D Micic, PR Gibson, SR Goeppinger, A Yarur, ... Inflammatory bowel diseases 24 (4), 849-860, 2018 | 50 | 2018 |
| Factors associated with readmission to the hospital within 30 days in patients with inflammatory bowel disease D Micic, JN Gaetano, JN Rubin, RD Cohen, A Sakuraba, DT Rubin, ... PLoS One 12 (8), e0182900, 2017 | 48 | 2017 |
Vincent B. YoungUniversity of MichiganVerified email at umich.edu
